Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates IMV has initiated plans to progress the clinical development of a Covid-19 vaccine candidate, to determine the clinical safety and immunogenicity.
Based on the company’s DPX delivery technology, the vaccine candidate DPX-COVID-19 comprises peptides that target epitopes from the novel coronavirus strain.
The peptide-based approach, along with the DPX platform, speeds up the development and production of a vaccine. IMV plans to advance its vaccine candidate into Phase I clinical trial.
IMV CEO Frederic Ors said: “Across our many clinical studies, we have observed DPX technology to elicit a robust immune response with a sustained effect, including in